AvantGen completes first Cancer therapeutic antibody program for TRL
Antibody discovery and optimization service provider, AvantGen claimed completion of its first cancer therapeutic antibody program in collaboration with Tanabe Research Laboratories USA also moving to commence a second program for the same.
As per the terms of the collaboration, Avantgen is liable for producing novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform. TRL possesses exclusive rights to commercialize and develop antibodies discovered by AvantGen.
Xiaomin Fan, Ph.D., founder and president of AvantGen said “AvantGen’s antibody discovery and optimization platforms have been extensively validated against hundreds of targets primarily through numerous NIH SBIR I and II funded projects. Since the recent introduction of our new, state-of-the-art human antibody discovery and optimization platform, this second project with TRL represents the 15th de novo antibody discovery project we have initiated specifically for our corporate partners.”
Roland Newman, Ph.D., chief scientific officer for TRL said “The therapeutic antibody discovery program conducted by AvantGen was highly collaborative and was accomplished faster than expected, without the need to further optimize the antibodies in order to meet TRL’s design goals.”